Revolution Medicines RVMD 深 滬
交易中 06-24 11:53:06 美东时间
167.20
-2.310
-1.36%
華盛通- 最 高170.6468
- 今 開170.50
- 成交量 106.23万股
- 最 低 166.43
- 昨 收 169.51
- 總市值 355.46亿
- 52周最高 171.25
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 34.00
- 委 比 -91.24%
- 總股本 2.13亿
- 歷史最高 171.25
- 量 比 1.03
- 振 幅 2.49%
- 歷史最低 14.08
- 每 手 1
- 風險率 40.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biotech breakout: iShares Biotechnology ETF hits all-time high
The biotechnology sector continued its advance on Tuesday, with the iShares Biotechnology ETF (IBB) reaching a record intraday high of $179.95 as investor interest in the industry remained strong. The...
今天 02:52
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines announces Steve Kelsey, M.D., president of R&D, will transition to senior advisor to CEO effective July 1, 2026, prior to his planned retirement in January 2027. Dr. Kelsey, who has led the company’s R&D since 2017, will continue to contribute his insights during the transition. The company will implement a new R&D leadership structure, with Alan Sandler, Jan Smith, and Xiaolin Wang assuming expanded roles. Revolution Medicin...
06-22 12:00
$1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 25.06% on an annualized basis producing an average annual return of 37.04%. Currently, Revolution Medicines has a market capitalization of $33.84 billion. Buying $1000 In RVMD: If an investor had bought $1000 of ...
06-18 22:45
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
Regeneron-backed Parabilis surges after record-setting IPO
Parabilis Medicines (PBLS) climbed more than 45% in its first trading session on Wednesday after the cancer drug developer backed by a recent research deal with Regeneron (REGN) made its public debut ...
06-11 01:30
BUZZ-IDEAYA Biosciences drops on $300 mln equity raise
BUZZ-IDEAYA Biosciences drops on $300 mln equity raise ** IDEAYA Biosciences' IDYA.O shares down 9.8% before the bell on Tues to $28.40 after $300 mln overnight follow-on priced ** IDYA late Mon sold ~5.56 mln shares and pre-funded warrants to buy ~5.56 mln shares at $27, a 14.2% discount to last sa
06-09 18:51
Why Is Tango Therapeutics Stock Soaring Monday?
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.
06-08 19:46
Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC
Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of
06-08 19:00
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics announced positive initial data from its Phase 1/2 trial of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The combination of vopimetostat and daraxonrasib showed a 92% objective response rate (ORR) and a 90% 6-month progression-free survival (PFS) rate in PDAC patients, with 100% disease control rate (DCR...
06-08 10:59
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
